Advancing Smoking Cessation: FDA and NIH Priorities

Goals and Objectives

This public meeting will address the need for novel smoking cessation products to help individuals of all ages, including underserved and vulnerable populations, stop smoking. The overall goal of the meeting is to stimulate novel product development to reduce rates of smoking and related chronic illnesses. The meeting format will include presentations and panel discussions.

In-person Attendance Information

This meeting will be held at the FDA White Oak Campus in the Great Room. Address: 10903 New Hampshire Avenue Bldg. 31, Room 1503, Silver Spring, MD 20903

The FDA will make every effort to accommodate persons with physical disabilities or special needs at public meetings. If a reasonable accommodation is needed, please indicate accordingly during registration and email [email protected]. Requests for sign language interpretation should be made at least 7 days before the public meeting. A request for ASL services should be sent directly to the FDA Interpreting Services Staff email account: [email protected]. The FDA White Oak campus and FDA shuttle are generally accessible to people with physical disabilities.

Additional information to assist with in-person attendance may be found within the following webpages: Public Meeting Information, Getting to the FDA, and Visitor Parking and Campus Map.

Virtual Attendance Information

The Zoom link will be provided to all registered attendees before the meeting. Virtual attendees can join the meeting by computer or phone.

Interested in submitting a request to make an oral presentation during the meeting?

Individuals attending the meeting in person may submit requests to make oral presentations at the public meeting. Select “In-person registration with presentation request,” follow the instructions presented in the confirmation email, and submit all details by 5 p.m. EDT, October 1, 2024.

Contact

For additional details and questions contact the meeting support team at [email protected].

Please note: In addition to this public meeting, the public can submit electronic or written comments to the docket until November 21, 2024, at 11:59 p.m. Eastern Time. Please visit the for the “Advancing Smoking Cessation: FDA and NIH Priorities” for more information about submitting comments.

Host or Publisher U.S. Food and Drug Administration's Center for Tobacco Products